A Prospective Real World Experience of Moxonidine Use in Indian Hypertensive Patients–Prescription beyond Current Guidelines
Objective: The primary objective of this study was to assess the use of moxonidine, a centrally acting anti–hypertensive agent in real world practice. Material and Methods: Patients who attended out-patients clinic with diagnosis of hypertension were enrolled in the study. Demographics with co-...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2013-10-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/3474/30-%205576_E(C)_F(P)_PF1(V_Pr_P)_PF2_Book_(P_V_P)_PFA(P).pdf |
Summary: | Objective: The primary objective of this study was to assess
the use of moxonidine, a centrally acting anti–hypertensive
agent in real world practice.
Material and Methods: Patients who attended out-patients
clinic with diagnosis of hypertension were enrolled in the
study. Demographics with co-morbid illnesses of all patients
were recorded. Patient’s prescriptions were recorded and antihypertensive medications were also analysed.
Results: A total of 990 patients were eligible during the study
period. Moxonidine was used in 4.54% of patients. Two groups
could be identified in moxonidine users – one Group with
resistant hypertension (30 patients, 3.03% of total, 66.66%
of moxonidine users) on multiple drugs to control BP and
another Group with intolerance to conventional, first line drugs
(15 patients 1.51% of total, 33.33% of moxonidine users).
Moxonidine was not used in newly diagnosed hypertension
cases. Resistant hypertension and renal failure predicted the
use of moxonidine. Majority of drug used was as per current
guidelines.
Conclusions: Our study results reflected real world practice
of current anti-hypertensive therapy. Patients generally receive
medications in accordance with current recommendations
and guidelines. Small but significant proportion of patients
may require use of drugs like moxonidine to control high BP.
Guidelines need to incorporate these real world practices. |
---|---|
ISSN: | 2249-782X 0973-709X |